Cochlear Cuts FY26 Profit Guidance as Market Softens but Doubles Down on Growth Investment

An announcement from Cochlear ( (AU:COH) ) is now available.

Cochlear has warned of softer-than-expected trading conditions in developed markets and rising uncertainty in the Middle East, prompting a cut to its FY26 underlying net profit guidance to $290 million-$330 million. The company cites hospital capacity constraints, weaker referrals from the hearing aid channel, declining consumer sentiment in key markets such as the U.S., and potential receivables provisions linked to the Middle East conflict, alongside lower gross margins and currency headwinds.

Despite the short-term pressures, Cochlear reports robust adoption of its Nucleus Nexa cochlear implant system, solid emerging-market demand and double‑digit constant-currency growth in both Services and Acoustics revenue in the third quarter. Management is accelerating a reshaping of the cost base to free up resources for growth in the adult and seniors segment, strengthen referral pathways, and continue investing in next‑generation technologies, including drug‑eluting electrodes and a totally implantable cochlear implant, to support long‑term sustainable expansion.

The most recent analyst rating on (AU:COH) stock is a Buy with a A$302.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.

More about Cochlear

Cochlear Limited is a global medical device company specialising in implantable hearing solutions, including cochlear implants, sound processors and bone conduction systems. The Australia-based group focuses on developed and emerging markets, targeting adults, seniors and children with severe to profound hearing loss, and leverages a broad R&D pipeline to sustain its market leadership.

Average Trading Volume: 247,863

Technical Sentiment Signal: Sell

Current Market Cap: A$11.25B

For a thorough assessment of COH stock, go to TipRanks’ Stock Analysis page.